Buprenorphine is a mixed opioid agonist-antagonist, which acts as a partial mu agonist and a kappa antagonist. The present study evaluated the acute effects of buprenorphine on cerebral glucose metabolism (CMRglc) in six human substance abusers using a double-blind, placebo-controlled, counterbalanced, crossover design. Each subject participated in two positron emission tomographic (PET) studies, 1 week apart, following the injection of buprenorphine (1 mg, intramuscularly) and placebo. Buprenorphine significantly reduced CMRglc and the regional cerebral KEY WORDS: Opioid; Buprenorphine; Glucose metabolism; Drug abuse; Human brain imaging Buprenorphine, a semi-synthetic opioid drug derived from thebaine, is currently marketed in the United States as an analgesic, and is approximately 25 to 50 times as potent as morphine (Cowan et al. 1977) . In hu man subjects, it produces effects that are typical of opi oid agonists (Heel et al. 1979) . These include analge-
Buprenorphine, a semi-synthetic opioid drug derived from thebaine, is currently marketed in the United States as an analgesic, and is approximately 25 to 50 times as potent as morphine (Cowan et al. 1977) . In hu man subjects, it produces effects that are typical of opi oid agonists (Heel et al. 1979) . These include analge-metabolic rate for glucose (rCMRglc) by up to 32% in all but three of 22 bilateral and in 4 midline regions (p < .05). No region showed an increase in rCMRglc. Buprenorphine also produced miosis, respiratory depression, and subjective ratings of euphoria and sedation in comparison to placebo (p < .05). These observations extend previous findings of reduced CMRgic following acute treatment with morphine and other nonopioid euphorigenic drugs.
lNeuropsychopharmacology 10: 157-170, 1994J sia, euphoria, sedation, pupillary constriction, and respiratory depression. Unlike many opioid agonists, its use is associated with limited physical dependence and minimal withdrawal symptoms Oasinski et al. 1978; Fudala et al. 1990) . Buprenorphine competes with selec tive ligands for binding to mu, delta, and kappa opioid receptors (Hambrook and Rance 1976;  Dum and Herz 1981; Villiger and Taylor 1981; Sadee et al. 1982) . Preclin ical studies have characterized the in vivo pharmaco logical activity of buprenorphine as that of a partial mu agonist (Martin et al. 1976; Cowan et al. 1977) and a kappa antagonist (Leander 1988; Negus and Dykstra 1988) . Its unique pharmacological proftle has led to the systematic evaluation and development of buprenor phine as a pharmacotherapy for opiate dependence and detoxifIcation (Jasinski et al. 1978; Bickel et al. 1988 ; Johnson et al. 1992) .
Although opioid receptors are widely distributed throughout the human brain, the density and patterns of distribution vary among receptor subtypes. Postmor tem studies have revealed high concentrations of mu 0893-133X/94/$0.00 receptors in striatum, amygdala, thalamus, and hypo thalamus; moderate levels of binding in neocortex (es pecially frontal and temporal regions); and limited bind ing in the pons and cerebellar cortex (Kuhar et al. 1973; Pfeiffer et al. 1982) . In contrast, kappa receptors are most abundant in neocortex (especially layers V and VI), amygdala, and hypothalamus, whereas very low den sities are present in most regions of the extrapyramidal motor system and the ventral tegmental area (Pfeiff er et al. 1982; Maurer et al., 1983) .
The present study was conducted to evaluate the in vivo effects of buprenorphine in the human brain. One approach to assessment of local brain function is metabolic mapping with 2-deoxyglucose McCulloch 1982; Sokoloff 1983) . Because glucose is a major substrate for cerebral energy metabolism (Sokoloff 1977; Siesjb 1978) , measurement of the re gional cerebral metabolic rate for glucose (rCMRglc) pro vides an index of local brain function (Sokoloff 1977; Sokoloff 1978) . The 2-deoxyglucose method, which was developed in rats , has been ex tended to human studies, using positron emission tomography (PET) and [F-18) fluorodeoxyglucose [FOG) Reivich et al. 1979 ) as a radiotracer for glucose metabolism. In a previous study, a euphori genic dose (30 mg) of morphine, a full agonist acting primarily at mu receptors with lower affinity for delta and kappa receptors Oaffe and Martin 1990), reduced ce rebral glucose utilization in human volunteers with his tories of polydrug abuse (London et al. 1990a ). The pres ent study similarly examined the acute effects of buprenorphine on global cerebral metabolic rate for glu cose (CMRglc) and rCMRglc in human subjects with histories of substance abuse. Simultaneous measures of subjective and physiological responses were ob tained. As both morphine and buprenorphine produce positive effects on mood and interact primarily with mu opioid receptors, we hypothesized that buprenorphine would decrease CMRglc and rCMRglc, as did mor phine. Nonetheless, we reasoned that the differences between the drugs in the spectra of affinities and ac tions at opioid receptor subtypes would be reflected in the anatomical distribution of rCMRglc changes.
METHODS

Subjects
The research subjects were adult male volunteers, recruited through local newspaper advertisements and paid for their participation. The study was completed while subjects resided at the General Clinical Research Center of Francis Scott Key Medical Center. The study was approved by the Institutional Review Boards of Johns Hopkins Medical Institutions and the affiliated NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO. 3 Francis Scott Key Medical Center. Subjects gave their written informed consent. An inclusion criterion for the subjects was current, sporadic opiate use without evi dence of physical dependence on opiates, as deter mined by history, observation, and urinalysis.
Aside from substance abuse and associated minor abnormalities in hepatic function, the subjects were deemed healthy according to results of a complete phys ical examination, electrocardiogram, and blood and urine assays. Urine specimens were collected prior to admission and daily throughout the study. Specimens were tested for the presence of illicit drugs using an EMIT system (Syva Co., Palo Alto, CA) and/or thin layer chromatography to ensure the absence of drugs other than those administered as part of the research protocol; no illicit drug use was found during the study. The subjects were maintained on a caffeine-free diet, but were allowed free access to cigarettes for 3 days prior to the fIrst PET study and for the intervening week be tween the two PET studies.
A total of nine subjects enrolled in the study; how ever, three were excluded prior to completion of the study for the following reasons: two because of a reported head injury prior to admission, and one be cause of a vasovagal reaction to insertion of an arterial catheter in preparation for the fIrst PET measurement. All subjects were in a drug-free state and were absti nent from all drugs of abuse (except for nicotine) prior to participation in the fIrst PET study.
The six subjects (ages 28 to 36 [mean = 31]) who completed the study were right-handed, black males with histories of intravenous drug abuse. Self-reports of drug-use history were obtained by personal inter view (Table 1 ). All subjects reported drinking alcohol, smoking cigarettes, and using cocaine and heroin in travenously. Two subjects reported using marijuana. The reported use of alcohol ranged from 1 to 2, to 60 drinks per week; cigarettes smoked per day ranged from 4 to 10; marijuana use ranged from 0 to 24 joints per week; cocaine use ranged from 0.15 to 6. 0 grams per week; and heroin use ranged from less than 2 to 50 mg per week. None of the subjects reported use of hallucinogens. Some subjects responded positively to questions about drug use, but did not provide meaning ful information regarding the amount and/or duration of drug use.
Experimental Design
The study was a double-blind, placebo-controlled cross over. Each subject completing the study participated in two PET measurements of CMRglc and rCMRglc, 1 week apart, following administration of either 1 mg of buprenorphine or placebo (sterile water) according to a counterbalanced randomized schedule. enriched [180]-labeled water. The radiochemical purity of the fmal product, determined using thin-layer chro matography or high-performance liquid chromatogra phy on an amino column eluted with aqueous acetoni trile, was greater than 98%. All preparations were sterile and apyrogenic.
Training and Preparation for PET Studies
Subjects were trained during the fi.rst week of admis sion prior to PET scanning in order to familiarize them with the procedures and to reduce the stress and nov elty of the test sessions. During each of two training sessions, the subject was seated in a quiet room with a trained research assistant and instructed to respond to the questions as though he had received either placebo or an opiate drug. The subject's eyes were cov ered with cotton gauze patches, and he wore head phones that presented constant white noise and a ''beep'' prompt every minute to both ears. When presented with each prompt, subjects were instructed to respond verbally to the question "How much do you feel the drug?", on a 5-point scale where 0 = not at all, Each subject was fi.tted with a molded thermoplas tic face mask that served as a head-stabilization device and alignment guide. Lines were drawn on the mask parallel to the inferior orbitomeatal (10M) plane and at 48, 56, 64, and 72 mm above this plane. The 10M plane was determined by external landmarks (the in ferior orbital notch and the tragus). The lines were used as guides for placement of the subject during the mag netic resonance imaging (MRI), x-ray computer assisted tomographic (CT), and PET scans.
All subjects received structural brain scans by ei ther MRI or CT to verify the absence of abnormal brain morphology. The images from these scans were co registered with those from the PET scans to enhance accuracy of placement of regions of interest (ROls) on the PET scans. Four of the subjects received MRI scans using a Resonex 4000 scanner (fi.eld strength = 0.4 Tesla, Te = 30 ms, Tr = 1450 ms, 256 x 256 matrix, two inter leaved plane sets) producing a proton density-weighted image. One subject was studied using a GE Signa scan ner (fi.eld strength = 1.5 Tesla) (Te = 20 ms, Tr = 600 ms, matrix 256 x 256, two interleaved plane sets) producing a Tl-weighted image. One subject received a CT scan using a Somatom DR 3 CT scanner. The MRI data sets comprised 25 image planes, each 4 mm thick on 4-mm centers, with no gap or overlap. The CT scans comprised 13 planes, each 8 mm thick on 8-mm centers, with no gap or overlap. All image plane sets covered from at least 8 to 104 mm above the 10M plane. Lines drawn on the face mask allowed placement and orien tation of the slices to be parallel to and contained within the 12 PET planes that were sampled; they had a nomi nal thickness of 14 mm on 8-mm centers, and a 6-mm overlap on each side.
Assay of Plasma Buprenorphine
Buprenorphine levels in arterial plasma (baseline and 45 minutes after test compound injection) were assayed in duplicate with a double antibody radioimmunoas say (Diagnostics Products Corp., Los Angeles, CA). Values are reported as ''buprenorphine equivalents" be cause the antibody cross-reacts approximately equally with buprenorphine and norbuprenorphine at low con centrations (1 to 5 ng/ml). Cross-reactivity with buprenorphine-3-glucuronide is observed at higher concentrations. The sensitivity of the assay was approx imately 0.1 ng/ml. The intra-and interassay coefficients of variation averaged 6.6% and 14.0%, respectively.
Physiological Measures
Pupillary diameter was determined from photographs taken in ambient room lighting using a Polaroid cam era with a 3 x magnifIcation 30 minutes prior to and at 50 and 100 minutes following injection of the test com pound. Heart rate and blood pressure were measured while the subjects were seated at -75, -20, -10, 0, 15, and 45 minutes, and respiratory rate and oral tem perature were taken at -75 and 45 minutes with respect to injection of the test compound at time zero. Arterial blood samples were collected for determination of Pa02, Paco2' pH, and bicarbonate at baseline and 13, 28, 45, 60, 90, and 120 minutes after injection of the test compound.
Subjective Measures
Responses to the beep prompts were obtained at 1-minute intervals for 15 minutes prior to and 30 minutes following injection of the test compound. Other self reported measures were paper and pencil tasks, and included visual analog scales, a short form of the Ad diction Research Center Inventory (ARC!) (Martin et al. 1971) , the Single Dose Questionnaire (SDQ) (Jaskin ski 1977), and the Profile of Mood States (POMS) (McNair et al. 1971) . These questionnaires were ad ministered at 30 minutes before and at 50 and 100 minutes after injection of the test compound. The vi sual analog scales were presented as 10 cm lines, marked on the left side with the description "not at all ," and on the right side with "extremely. " Along the ana log line, the subject marked his response to the follow ing questions: "How strong was the drug effect?, " "How much did you like the drug?," "Did the drug have any good effects?, " "How high did you feel?," "Do you want to take this drug again?," and "How much do you desire opiates right now? " The short form of the ARC! consists of forty-nine true/false questions and contains five major sub-scales: Morphine-Benzedrine Group (MBG) [ (Martin et al. 1971 ). On the pharmacological class questionnaire, the subject categorized the drug effect as being most similar to one of ten classes of psychoactive drugs; the questionnaire provided descriptive titles for and examples of each of the following classes: placebo, opiates, opiate antago nists, phenothiazines, barbiturates and sleeping medi cations, antidepressants, hallucinogens, benzodiaze pines, stimulants, and others.
PET Measurement of rCMRglc
On each day that PET scanning was performed, subjects received a standard nonketogenic 358 calorie (18 g pro tein, 43 g carbohydrates, and 10 g fat) breakfast. They were then fasted for 4 to 6 hours before the FDG injec tion, which occurred between 11:00 AM and 2:30 PM. They were not allowed to smoke for 6 hours before the FDG injection and during the radiotracer uptake and
scanning. An intravenous infusion of 0.45% NaCl was initiated in a forearm vein at least 3 hours prior to the FDG injection. A radial arterial catheter was also in serted after the administration of local anesthetic (0.5% lidocaine HCl, subcutaneously) in the arm opposite to the venous catheter. Thirty minutes before injection of the test compound, the subject was seated with eyes covered and headphones in place and instructed to re lax. At 15 minutes after the injection of test compound, 5 mCi of FDG in NaCl (volume ranged from 2.5 to 6.5 ml) was infused through the forearm vein catheter over 30 seconds, followed by 20 to 50 ml of 0.9% NaCl. The IS-minute interval between injection of FDG and bu prenorphine was selected because physiological and subjective responses to buprenorphine have been ob served within 15 to 30 minutes of subcutaneous and intramuscular administration of the drug (Jasinski et al. 1989; Ouellete 1982) .
Approximately thirty 1.0 to 1.5 ml arterial blood samples were drawn according to a schedule of decreas ing frequency, beginning immediately after commence ment of the FDG injection and continuing until the end of PET scanning. Blood samples were centrifuged, and aliquots of plasma were assayed for radioactivity and glucose concentration in a well scintillation spectrom eter and a glucose analyzer (Glucose Analyzer 2, Beck man Instruments, Irvine, CA), respectively. As is the common procedure, PET scanning began PET images were reconstructed from the raw data with a standard filtered back-projection algorithm and a high-resolution Shepp-Logan filter with a resolution of 8 mm. Attenuation correction was performed by visually placing an ellipse around the contour of the scalp on the reconstructed PET image. Attenuation was calculated assuming a uniform attenuation coefficient (� = 0.088/cm, measured for water in the NeuroECAT scanner), and the raw data were corrected and recon structed again.
Measures of brain radioactivity were converted into estimates of metabolic rates from PET data, plasma ra dioactivity, and glucose concentration, using published values of the rate constants for the transport of FDG between brain and plasma, FDG phosphorylation and dephosphorylation in brain (K1 = .102 min -1, K 2 = .13 min -1, K3 = .062 min -1, and � = .0068 min -1 ), the lumped constant (LC = .43), and an operation equa tion (Huang et al. 1980) . The PET scanner and the well counter were cross-calibrated daily using a cylindrical phantom containing 1 to 2 mCi of FDG in water.
Data from PET scans were converted to values of rCMRglc and were displayed with an image analysis system (LOATS Associates Inc., Westminster, MD). The resultant images, together with the associated MRI or CT images, were transferred to the IMAGE 1.44 pro gram run on a Macintosh computer (Rasband 1990) . A standard template of ROIs was constructed with refer ence to an anatomical atlas (Hanaway et al. 1980) . The template consisted of 42 circles and six ellipses that identified brain areas in eight of the 25 MRI slices. For fi.ve of the subjects, MRI and PET scans from each study were compared with the anatomical atlas to select those eight planes that best matched the planes in the refer ence set for the ROI analysis. It was not possible to ob tain MRI scans for one of the subjects; in this case, im ages from the CT scan were used for co-registration with PET scans.
The size selected for each ROI was based upon the size of the brain area and the spatial resolution of the PET scanner. Ventricles and non-brain matter (bone and cerebrospinal fluid) were excluded from measurement by visual inspection of the densities of structural im ages. For isolated structures (e.g., caudate nucleus), the ROI was made to fit within the structure; for contigu ous areas (e.g., cortical gyri), the ROls were 7 to 15 mm in diameter. To minimize partial volume effects in small structures, a single ROI was placed on that slice that best passed through the middle of the structure, even if the structure was visible in adjacent slices.
ROI analysis was performed by two independent raters (S. Gilson and J. Schmidt). The drug treatment for each PET study was concealed from both raters. Each of the 48 ROls was transferred from the standard tem plates onto the eight MRI or CT slices selected for each subject. Minor adjustments in placement of the ROls were performed as indicated by anatomical landmarks in the structural image. Structural (MRI or CT) and PET images were then manually co-registered using visual cues, particularly outer edges in the overlaid images. The ROIs were transferred using a modified version of the IMAGE 1.44 program for ROI placement and anal ysis (Rasband 1990 ). Inter-rater reliability was tested with Pearson correlation coefficients. The criterion for acceptability of agreement between the raters was ar bitrarily set at a correlation coefficient no greater than 0.8 for each individual subject. The criterion of r = 0.8 was selected because it is the minimum r that differs significantly from zero at p = .05 and n = 6. When the coefficient was less than 0.8, the ROls were placed again and measurements retaken.
Whole-slice and whole-brain average CMRglc were determined by tracing the outlines of the brain on struc tural images that were co-registered with the PET im ages and transferring the outlines to the PET images. The brain contour was determined by using visual cues for segmentation of brain tissue from ventricles and ex tracerebral tissues. The process involved a threshold based tracing algorithm with subsequent visual correc tion. The area-weighted average of glucose metabolism in the whole slice was calculated from the metabolic rate in each pixel included within the contour. Global CMRglc was calculated as an area-weighted average of all pixels within the contours of all slices used in the study and was used as the denominator to calculate nor malized rCMRglc.
Statistical Analysis
Data were analyzed using the Statistical Analysis Sys tem (SAS) Version 6.07 (SAS Institute, Inc., Cary, NC). All statistical tests were two-tailed, and the criterion for significance was p < .05. Data obtained in assays of CMRglc and rCMRglc were subjected to a separate anal ysis of variance (ANOV A) for each brain region. In cases of midline structures, the ANOVA was one-way, test ing the effect of buprenorphine. Data from bilateral regions were analyzed by two-way ANOV A with hemi sphere and drug treatment as the factors. Values of F were not corrected for multiple comparisons. When significant F values were obtained for main effects, in dividual means were compared using Tukey's post hoc tests (with Bonferroni corrections when appropriate). Values for cardiovascular measures (systolic and di astolic blood pressure, heart rate), arterial blood gases (Paco2 and Pa02), pH, and subjective effects were ana lyzed using two-way ANOV A, with drug treatment (placebo, buprenorphine) and time of measurement as the factors. Post hoc comparisons determined the time when changes from baseline were statistically signifIcant after buprenorphine or placebo administra tion. Plasma glucose concentrations were averaged over the PET measurement period and were analyzed by Student's paired t-test.
RESULTS
Plasma samples taken before and at 45 minutes after injection of placebo (30 minutes after injection of FOG)
were negative for buprenorphine. The mean (SO) buprenorphine level at 45 minutes after injection of the drug was 5.48 (1.67) ng/ml, indicating that buprenor phine was absorbed during the period of FOG uptake.
Physiological Effects
Oata on physiological parameters are shown in Table   2 . Buprenorphine signifIcantly constricted pupil di- Drug Strl!ngth
Time (m,nules)
Time (minules)
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Subjective Effects
The results obtained on visual analog scales are shown in Figure 2 . Measures of positive mood ("good effects"
and "high") were signifIcantly elevated by buprenor phine in comparison to placebo (p < .05). Subjects reported signifIcant ratings of " drug strength" and '1ik
ing" for buprenorphine, and a desire "to take the drug again" (p < .05). Buprenorphine produced a small but nonsignifIcant increase in "desire for opiates." On the SOQ, subjects reported signifIcantly increased ratings of "nodding," "high," "liking," and "feeling the drug" For these subjects, recognition of the onset of a drug effect occurred within 7 minutes of the injection on av erage. Two subjects failed to report a buprenorphine effect in response to the beep-prompt question. How ever, these two subjects did report signifIcant drug effects on other questionnaires following completion of the FOG uptake period. The average beep prompt scores for the entire group increased from 0 to a maxi mum of 1.5 following buprenorphine.
Scores on the PCAG scale of the ARCI were higher when the subjects received buprenorphine than when they received placebo (F[l,S] = 10.0; P = .025). Time (mlnules) Figure 2 . The effects of bupre norphine (1 mg, 1M, given at time 0) and placebo on six visual ana log measures ("drug strength," "liking," "good effects," "high," "want to take the drug again," and "desire for opiates") are shown. The asterisks (*) indicate signifI cant differences from placebo for each respective time point (p< .05; Tukey post hoc analyses). B refers to baseline measures collected 15 minutes before injection of drug.
norphine administration. Conversely, scores on the Benzedrine scale were lower after buprenorphine than after placebo (F[1,5] = 7.03; P = .045). There were no signifIcant main effects on the Amphetamine, MBG, or LSD scales.
Regional Cerebral Glucose Utilization
Comparison of measurements of rCMRglc in the 48 ROls (22 bilateral and four midline regions) by two in dependent raters yielded correlation coefficients rang ing from 0.60 to 0.99 for data on individual ROls. When data were collapsed across ROls, mean inter-rater corre- NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO. 3 lation coefficients for each of the six subjects ranged from 0.80 to 0.97 (mean = 0.92).
Buprenorphine signifIcantly (both raters) reduced rCMRglc by up to rv 30% in 17 of the 22 bilateral regions and all midline structures analyzed (Table 3 ; Fig. 3 ). Table 1 ) showed essen tially no change (+0.43%). The lack of response by this subject was not accounted for by either a low plasma level of buprenorphine or a self-reported drug history that was markedly different from the rest of the group. Mean (SO) CMRglc values for the six subjects were 6.46 (1.08) and 5.08 (0.72 mg/100g/min) for placebo and buprenorphine treatments, respectively. The decrease in CMRglc ranged from 16.6% to 32.6%, with a median decrease of 21.4%. The correlation between the percent change in CMRglc and buprenorphine levels in plasma failed to reach statistical signifIcance for the small num ber of subjects tested (r = .77).
Normalized values for rCMRglc were obtained by dividing the raw rCMRglc by CMRglc for each subject. Analysis of the normalized data revealed no signifIcant main effects of drug or hemisphere and no signifIcant drug x hemisphere interactions. These fIndings were consistent across data from the two raters.
CONCLUSION
The present study is the fIrst demonstration that buprenorphine reduced rCMRglc and CMRglc in hu man subjects. This effect was global and was consis tent with previous fIndings demonstrating a reduction of CMRglc in response to an equieuphorigenic dose of morphine (London et al. 1990a ). Thus, effects on rCMRglc did not distinguish between the actions of morphine, a pure opioid agonist, and buprenorphine, a mixed agonist/antagonist. However, the decrement in CMRglc (21%) following buprenorphine exceeded that observed following morphine (10%). This dis crepancy may be attributable to individual differences in the research subjects in the two studies, or to differ ences in the potencies or receptor binding profIles of the drugs.
Buprenorphine and Cerebral Glucose Metabolism 165
Effects of buprenorphine on rCMRglc follow the distribution of opioid receptors in the human brain only to some extent (Kuhar et al. 1973; Frost et al. 1985) . For example, some subcortical brain regions (e.g., pons) ex hibited decreased metabolism in response to buprenor phine, despite low to negligible levels of opioid recep tors. In this regard, the literature on cerebral metabolic responses to psychoactive drugs in rats predicts that the distribution of changes in rCMRglc in response to buprenorphine would not directly parallel the densities of opioid receptors. Discrepancies between rCMRglc changes and the distributions of relevant receptors in brain have been observed using the 2-deoxy-o-[1-14C] glucose method in rats treated with a variety of drugs, including muscarinic agonists (Dow-Edwards et al. 1981; Dam et al. 1982) , and agonists and antagonists for y-aminobutyric acid (GABAA) receptors (Palacios et al. 1981) . Because values of rCMRglc reflect local, direct interactions with receptors as well as secondary changes that are due to metabolism in afferents (Kennedy 1983) , it is plausible that metabolic maps need not reflect rele vant receptor maps.
Consistent with the respiratory depressant proper ties of opioid agonists (Jaffe and Martin 1990) and previ ous studies with buprenorphine (e.g., Pasqualucci et al. 1987) , buprenorphine reduced respiration, as reflected in reductions of respiratory rate and Pa02 and increases in Pac02' It seems unlikely, however, that the decre ments in rCMRglc and CMRglc reported here could be due to the mild hypoxia that was produced. First, ex treme hypoxia can elevate CMRglc (28% for Pa02 = 34.6 mm Hg) (Cohen et al. 1967 ) by stimulating anaerobic glycolysis (Siesj61978). Furthermore, although elevated CO2 can reduce cerebral glucose metabolism by inhibit ing hexokinase and phosphofructokinase (Siesj61978), preliminary studies in our laboratory have shown that hypercapnia at a level similar to that seen in the current study did not reduce CMRglc (J .M. Stapleton, R. Gray son, D.F. Wong, E. Shaya, and E.D. London, unpub lished observations). In those studies, four young healthy males were administered 3% to 5% C0 2 through a breathing mask prior to and during study with the FOG procedure. 
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FOG PET Scans Control Buprenorphine of the radiotracer until measurement of radioactivity in the brain (i.e., scanning with PET methods), the method is biased primarily to reflect brain activity in the fIrst 10 to 15 minutes after radiotracer administration (McCul loch 1982) . In the present study, signifIcant hypercap nia and hypoxia were not apparent until approximately 30 and 45 minutes, respectively, after the FOG injection. Therefore, it is unlikely that the mild hypercapnia pro duced by buprenorphine during the early part of the FDG measurement period could account for the ob served decrements in rCMRglc.
It is important to consider the potential interaction between prior drug experience and rCMRglc response to psychoactive drugs. It is well known that the be havioral and pharmacological histories of subjects can influence their response to drugs (Barrett and Witkin 1986) . Furthermore, previous PET studies have demon strated that subjects with histories of cocaine abuse have defIcits in glucose metabolism as compared with con trols (Volkow et a1. 1992) . Subjects in the present study had extensive drug histories, including several years of illicit substance abuse, previous physical dependence and detoxifIcation, and experience with a wide variety of drugs. Differences in drug history may have ac counted for some of the between-subject differences observed in the present study. Furthermore, pharma cological fIndings in polysubstance abusers should not be generalized to normal subjects without histories of drug use.
Buprenorphine produced an array of physiologi cal and subjective effects during the period of FDG uptake, consistent with the classifIcation of this drug as a partial mu opioid agonist. These effects included mild respiratory depression, miosis, and increased sub jective ratings of positive mood and sedation. The mi otic effects were evident within 50 minutes of drug ad ministration and showed no sign of recovery at the last measurement, 2 hours after administration of the drug. The magnitude and duration of miosis were compara ble to those produced previously by similar doses of buprenorphine (Jasinski et a1. 1989) . The increased rat ings of positive mood, liking for the drug, and seda tion are consistent with previous reports (Jaskinski et a1. 1989; Preston and Jasinski 1991; Weinhold et al. 1992) . The onset of the subjective effects of buprenor phine, as measured by the beep-prompted responses, occurred within 7 minutes of the intramuscular injec tion. Because of the overlap in time course for the cere bral metabolic and subjective effects of buprenorphine, it is possible that these effects are related causally. Nonetheless, one could only speculate whether the ce rebral metabolic response is involved in the neural mechanism that produces the subjective effects or, al ternatively, is a response to the subjective effects.
The observed reduction in cortical rCMRglc after NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.3 a euphorigenic dose of buprenorphine extends the fIndings of reduced cortical rCMRglc following adminis tration of other euphorigenic drugs. Cerebral metabolic decreases have been observed following acute adminis tration of benzodiazepines (Buchsbaum et a1. 1987; de Wit et a1. 1991) , barbiturates (Theodore et al. 1986 ), am phetamine (Wolkin et a1. 1987) , cocaine (London et al. 1990b) , morphine (London et al. 1990a ), ethanol (de Wit et a1. 1990 Volkow et a1. 1990) , and nicotine (Stapleton et al. 1992) . The reduction of cortical metabolism across the range of major self-administered and/or abused drug classes, despite the distinctive pharmacological activities of these drugs, suggests that reduced cortical glucose metabolism may serve as a common compo nent in the reinforcing action and subjective response to abused drugs (for review see London and Morgan 1993) .
